MCID: BRR002
MIFTS: 43

Barrett's Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Barrett's Adenocarcinoma

MalaCards integrated aliases for Barrett's Adenocarcinoma:

Name: Barrett's Adenocarcinoma 12 14 69
Adenocarcinoma Arising in Barrett's Mucosa 12
Barrett Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7941
NCIt 47 C7027
UMLS 69 C1332460

Summaries for Barrett's Adenocarcinoma

MalaCards based summary : Barrett's Adenocarcinoma, also known as adenocarcinoma arising in barrett's mucosa, is related to tendon sheath lipoma and congenital disorder of glycosylation, type if. An important gene associated with Barrett's Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Development HGF signaling pathway and Chks in Checkpoint Regulation. The drugs Menthol and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and lymph node, and related phenotypes are cellular and behavior/neurological

Related Diseases for Barrett's Adenocarcinoma

Diseases related to Barrett's Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
id Related Disease Score Top Affiliating Genes
1 tendon sheath lipoma 10.8 PTGS2 TP53
2 congenital disorder of glycosylation, type if 10.8 ERBB2 TP53
3 endocervicitis 10.8 ERBB2 TP53
4 extracranial neuroblastoma 10.7 ERBB2 TP53
5 cervical adenoid cystic carcinoma 10.7 CDKN2A TP53
6 colon neuroendocrine neoplasm 10.7 ERBB2 TP53
7 cystic kidney disease 10.7 ERBB2 TP53
8 split hand split foot nystagmus 10.7 CDKN2A TP53
9 brenner tumor of the vagina 10.7 ERBB2 TP53
10 leiomyoma cutis 10.7 CDKN2A TP53
11 skeletal tuberculosis 10.7 CDKN2A ERBB2
12 anal squamous cell carcinoma 10.7 CDKN2A TP53
13 testis seminoma 10.7 CDKN2A ERBB2
14 rectum squamous cell carcinoma 10.7 CDKN2A TP53
15 breast myoepitheliosis 10.7 CDKN2A TP53
16 brachial amelia, forebrain defects and facial clefts 10.7 CDKN2A PTGS2
17 ritter's disease 10.7 CDKN2A TP53
18 brenner tumor of ovary 10.7 ERBB2 TP53
19 coccidiosis 10.7 CDKN2A TP53
20 duodenum cancer 10.6 CDKN2A TP53
21 penis paget's disease 10.6 CDKN2A TP53
22 vulva squamous cell carcinoma 10.6 CDKN2A ERBB2
23 breast fibrosarcoma 10.6 ERBB2 TP53
24 otitis externa 10.6 ERBB2 TP53
25 myotonia congenita 10.6 CDKN2A ERBB2
26 retinal detachment 10.6 CDKN2A TP53
27 active vestibular meniere's disease 10.6 CDKN2A PTGS2
28 phalanx chondroma 10.6 CDKN2A TP53
29 prostatitis 10.6 OGG1 TP53
30 olfactory neural tumor 10.6 CDKN2A TP53
31 non-suppurative otitis media 10.6 CDKN2A TP53
32 organ system benign neoplasm 10.5 ERBB2 TP53
33 pancreatic agenesis 10.5 CDKN2A TP53
34 breast myoepithelial neoplasm 10.5 KRAS TP53
35 cartilage cancer 10.5 ERBB2 TP53
36 coloboma of inferior eyelid 10.5 KRAS TP53
37 rectum kaposi's sarcoma 10.5 ERBB2 PTGS2 TP53
38 microphthalmia/anophthalmia/coloboma spectrum 10.5 KRAS TP53
39 secondary pulmonary hemosiderosis 10.5 CDKN2A TP53
40 rete testis neoplasm 10.5 CDKN2A PTGS2
41 animal phobia 10.5 ERBB2 TP53 XRCC1
42 dysembryoplastic neuroepithelial tumor 10.5 ERBB2 PTGS2 TP53
43 esophagus squamous cell carcinoma 10.5 CDKN2A PTGS2 TP53
44 malignant syringoma 10.4 KRAS TP53
45 group b strep disease in newborns 10.4 ERBB2 TP53
46 fasciolopsiasis 10.4 CDKN2A PTGS2 TP53
47 atrophic gastritis 10.4 CDKN2A PTGS2 TP53
48 ductal carcinoma in situ 10.4 CDKN2A ERBB2 TP53
49 orbital lymphangioma 10.4 CDKN2A PTGS2 TP53
50 anaerobic pneumonia 10.4 CDKN2A ERBB2 TP53

Graphical network of the top 20 diseases related to Barrett's Adenocarcinoma:



Diseases related to Barrett's Adenocarcinoma

Symptoms & Phenotypes for Barrett's Adenocarcinoma

MGI Mouse Phenotypes related to Barrett's Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 ADIPOR1 CDKN2A ERBB2 KRAS OGG1 PTGS2
2 behavior/neurological MP:0005386 10.08 XRCC1 ADIPOR1 CDKN2A ERBB2 KRAS OGG1
3 homeostasis/metabolism MP:0005376 10.02 KRAS OGG1 PTGS2 TP53 XRCC1 ADIPOR1
4 embryo MP:0005380 9.95 CDKN2A ERBB2 KRAS PTGS2 RAD51 TP53
5 digestive/alimentary MP:0005381 9.91 CDKN2A ERBB2 FHIT KRAS PTGS2 TP53
6 mortality/aging MP:0010768 9.91 CDKN2A ERBB2 FHIT KRAS OGG1 PTGS2
7 liver/biliary system MP:0005370 9.8 CDKN2A KRAS OGG1 PTGS2 TP53 ADIPOR1
8 muscle MP:0005369 9.63 ADIPOR1 CDKN2A ERBB2 KRAS PTGS2 TP53
9 neoplasm MP:0002006 9.56 OGG1 PTGS2 TP53 XRCC1 CDKN2A ERBB2
10 normal MP:0002873 9.17 ADIPOR1 ERBB2 KRAS OGG1 PTGS2 TP53

Drugs & Therapeutics for Barrett's Adenocarcinoma

Drugs for Barrett's Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Liver Extracts Phase 4
6 Protective Agents Phase 4,Phase 3,Phase 2
7 Antiemetics Phase 4
8 Anti-Inflammatory Agents Phase 4,Phase 3
9 Antineoplastic Agents, Hormonal Phase 4
10 Autonomic Agents Phase 4
11 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
12 glucocorticoids Phase 4
13 Hormone Antagonists Phase 4,Phase 3,Phase 2
14 Hormones Phase 4,Phase 3,Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
16 Methylprednisolone acetate Phase 4
17 Methylprednisolone Hemisuccinate Phase 4
18 Neuroprotective Agents Phase 4
19 Peripheral Nervous System Agents Phase 4,Phase 3
20 Prednisolone acetate Phase 4
21 Prednisolone hemisuccinate Phase 4
22 Prednisolone phosphate Phase 4
23
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
24
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
25
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
26
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 5310940 9887054 43805 6857599
27
Pancrelipase Approved Phase 3,Phase 2 53608-75-6
28
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 4594 9579578
29
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
30
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
31
Paclitaxel Approved, Vet_approved Phase 3,Phase 2 33069-62-4 36314
32
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
33
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
34
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
35
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
36
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
37
Camptothecin Experimental Phase 3,Phase 2 7689-03-4
38 Micronutrients Phase 3,Phase 2,Phase 1
39 Trace Elements Phase 3,Phase 2,Phase 1
40 Antidotes Phase 3,Phase 2
41 Antimetabolites Phase 3,Phase 2
42 Antimetabolites, Antineoplastic Phase 3,Phase 2
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
44 Bone Density Conservation Agents Phase 3,Phase 2
45 Calcium, Dietary Phase 3,Phase 2
46 Immunosuppressive Agents Phase 3,Phase 2
47 topoisomerase I inhibitors Phase 3,Phase 2
48 Topoisomerase Inhibitors Phase 3,Phase 2
49 Vitamin B Complex Phase 3,Phase 2
50 Vitamins Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 84)

id Name Status NCT ID Phase Drugs
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4 Prednisolone
3 Reduction in Symptomatic Esophageal Stricture Formation Terminated NCT02039115 Phase 4 prednisone;placebo
4 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
5 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00003594 Phase 3 irinotecan;fluorouracil;leucovorin calcium;oxaliplatin
6 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
7 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
8 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Active, not recruiting NCT00357682 Phase 3 Esomeprazole;Esomeprazole;Aspirin
9 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
10 Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer Terminated NCT00002976 Phase 3 conjugated estrogens
11 Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus Unknown status NCT00903136 Phase 1, Phase 2
12 Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer Completed NCT00411151 Phase 2 Sunitinib-Malate
13 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
14 Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer Completed NCT00281736 Phase 2 HPPH
15 Novel Method of Surveillance in Barrett's Esophagus Completed NCT00955019 Phase 2
16 Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer Completed NCT00032123 Phase 2 erlotinib hydrochloride
17 S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach Completed NCT00004233 Phase 2 fluorouracil;leucovorin calcium;triacetyluridine
18 S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer Completed NCT00003018 Phase 2 dipyridamole;fluorouracil;leucovorin calcium;mitomycin C
19 Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma Recruiting NCT02018367 Phase 2 Proflavine, high resolution imaging
20 Autologous Cell Sheets Transplantation After ESD in the Esophagus Recruiting NCT02455648 Phase 2
21 Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus Recruiting NCT01298999 Phase 2 YF476;Placebo
22 Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer Recruiting NCT02839343 Phase 2 mFOLFIRINOX;FOLFOX
23 S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Recruiting NCT02562716 Phase 2 Fluorouracil;Gemcitabine Hydrochloride;Irinotecan Hydrochloride;Oxaliplatin;Paclitaxel Albumin-Stabilized Nanoparticle Formulation
24 Radiofrequency Ablation for Barrett Oesophagus With Low Grade Dysplasia Active, not recruiting NCT01360541 Phase 2
25 YF476 in Barrett's Esophagus Enrolling by invitation NCT02597712 Phase 2 YF476;YF476 placebo
26 Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) Terminated NCT01528501 Phase 2 Panobinostat (LBH589)
27 S0425 Oxaliplatin, Capecitabine, and RT in Treating Patients W/Stomach Cancer That Can Be Removed By Surgery Terminated NCT00335959 Phase 2 capecitabine;oxaliplatin
28 Effect of Zinc on Barrett's Metaplasia Unknown status NCT01984580 Phase 1 zinc gluconate
29 Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus Completed NCT01238042 Phase 1 HPPH
30 Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus Completed NCT01236443 Phase 1 HPPH
31 Esophageal Protocol for Detection of Neoplasia in the Digestive Tract Completed NCT01391208 Phase 1 GI heptapeptide
32 A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract Completed NCT01630798 Phase 1 GI heptapeptide
33 VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions Completed NCT02129933 Phase 1 Bevacizumab-IRDye800CW
34 Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions Active, not recruiting NCT03205501 Phase 1 IV-administation of EMI-137
35 Aceto-whitening in the Assessment of Gastrointestinal Neoplasia Unknown status NCT01618643
36 Studying Genes for Barrett's Esophagus in Brothers and Sisters Unknown status NCT00516347
37 Familial Barrett's Esophagus Unknown status NCT00288119
38 Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy Unknown status NCT02284802
39 Confocal Laser Endomicroscopy in Patients With Eosinophilic Esophagitis Unknown status NCT01234376
40 ESD Versus EMR for Treatment of Early Barrett`s Adenocarcinoma Completed NCT01871636
41 Endoscopic Tri-Modal Imaging in Patients With Barrett's Esophagus Completed NCT00586989
42 A Comparison of Volumetric Laser Endomicroscopy (VLE) and Endoscopic Mucosal Resection (EMR) in Patients With Barrett's Dysplasia or Intramucosal Adenocarcinoma Completed NCT01862666
43 Preliminary Longitudinal Validation of Biomarkers Predictive of Barrett's Esophagus Completed NCT00844077
44 Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management Completed NCT02075905
45 Micro-RNA (miR) Expression in Upper Gastrointestinal Mucosal Tissue Completed NCT00909350
46 Prevalence of Dysplasia of the Gastric Cardia Completed NCT01787864
47 Methylene Blue Chromoendoscopy in Barrett's Esophagus Completed NCT00587652
48 Early Detection of Barrett's Esophagus Completed NCT00081354
49 Detection Of Neoplastic Tissue in Barrett's Esophagus With In vivO Probe-based Confocal Endomicroscopy Completed NCT00795184
50 Epidemiology of Barrett's Esophagus: A Population Based Study Completed NCT01286155

Search NIH Clinical Center for Barrett's Adenocarcinoma

Genetic Tests for Barrett's Adenocarcinoma

Anatomical Context for Barrett's Adenocarcinoma

MalaCards organs/tissues related to Barrett's Adenocarcinoma:

39
Bone, Liver, Lymph Node, Endothelial, Heart

Publications for Barrett's Adenocarcinoma

Articles related to Barrett's Adenocarcinoma:

(show top 50) (show all 99)
id Title Authors Year
1
Tumor location is a risk factor for lymph node metastasis in superficial Barrett's adenocarcinoma. ( 28924592 )
2017
2
Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells. ( 27932981 )
2016
3
A case of simultaneous esophageal squamous cell carcinoma and Barrett's adenocarcinoma. ( 27220657 )
2016
4
A case of Barrett's adenocarcinoma with marked endoscopic morphological changes in Barrett's esophagus over a long follow-up period of 15a88years. ( 26946036 )
2016
5
Single center experience of endoscopic submucosal dissection (ESD) in early Barrett's adenocarcinoma. ( 25294533 )
2015
6
STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas. ( 23912451 )
2014
7
Volumetric laser endomicroscopy detects subsquamous Barrett's adenocarcinoma. ( 24496431 )
2014
8
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study. ( 25133047 )
2014
9
The evil lies below the surface: Subsquamous tumor extension in Barrett's adenocarcinoma. ( 26134612 )
2014
10
Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma. ( 24565073 )
2014
11
Reduced expression of I+GlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma - a possible biomarker to predict the malignant potential of Barrett's oesophagus. ( 24117499 )
2013
12
Differences in the Characteristics of Barrett's Esophagus and Barrett's Adenocarcinoma between the United States and Japan. ( 23606979 )
2013
13
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. ( 23604115 )
2013
14
Barrett's adenocarcinoma in long-segment Barrett's esophagus successfully detected by narrow-band imaging with magnifying endoscopy. ( 23617678 )
2013
15
Current status of endoscopic diagnosis and treatment of superficial Barrett's adenocarcinoma in Asia-Pacific region. ( 23617667 )
2013
16
Small Barrett's adenocarcinoma, 3 mm in size, in long-segment Barrett's esophagus detected after 4 years of follow up. ( 23617677 )
2013
17
A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model. ( 23288782 )
2013
18
Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma. ( 22690932 )
2012
19
MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. ( 22365974 )
2012
20
Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma. ( 23180947 )
2012
21
Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. ( 22399496 )
2012
22
How much length of the distal esophagus is removed by transhiatal approach for squamous cell carcinoma and Barrett's adenocarcinoma in Japanese patients? ( 22234066 )
2011
23
Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. ( 20677919 )
2011
24
A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component. ( 26190613 )
2011
25
Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. ( 21423218 )
2011
26
Barrett's adenocarcinoma of the esophagus: better outcomes through new methods of diagnosis and treatment. ( 21629515 )
2011
27
Barrett's adenocarcinoma 52 years after subtotal esophagectomy for pediatric peptic stricture. ( 20103354 )
2010
28
Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. ( 20840671 )
2010
29
A case of early Barrett's adenocarcinoma repeatedly developing multiple metachronous lesions shortly after endoscopic therapy: an analysis for genetic and epigenetic alterations. ( 20650453 )
2010
30
Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. ( 18663352 )
2009
31
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. ( 19620873 )
2009
32
DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. ( 18664505 )
2009
33
Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. ( 19828957 )
2009
34
Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms. ( 18202808 )
2008
35
No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study. ( 18349297 )
2008
36
Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma. ( 18513411 )
2008
37
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. ( 18676772 )
2008
38
Immunohistochemical expression of p63 in esophageal Barrett's adenocarcinoma. ( 21479434 )
2008
39
Results of a multimodal therapy in patients with stage IV Barrett's adenocarcinoma. ( 18802733 )
2008
40
Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. ( 17376806 )
2007
41
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. ( 17227303 )
2007
42
Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. ( 17227311 )
2007
43
Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett's adenocarcinoma. ( 17185078 )
2007
44
Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression. ( 17636545 )
2007
45
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. ( 17244951 )
2006
46
Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas. ( 17032501 )
2006
47
Familial Barrett's adenocarcinoma. ( 16542304 )
2006
48
Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor. ( 16720317 )
2006
49
Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. ( 16921482 )
2006
50
Esophageal (Barrett's) adenocarcinoma is not associated with Epstein-Barr virus infection: an analysis of 162 cases. ( 15929074 )
2005

Variations for Barrett's Adenocarcinoma

Copy number variations for Barrett's Adenocarcinoma from CNVD:

7 (show top 50) (show all 60)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39411 10 114900000 119100000 Gain ABLIM1 Barrett''s adenocarcinoma
2 39412 10 114900000 119100000 Gain AFAP1L2 Barrett''s adenocarcinoma
3 42467 10 34500000 38800000 Gain CCNY Barrett''s adenocarcinoma
4 42468 10 34500000 38800000 Gain CUL2 Barrett''s adenocarcinoma
5 65755 12 21200000 26300000 Gain SSPN Barrett''s adenocarcinoma
6 66184 12 26300000 27700000 Gain ARNTL2 Barrett''s adenocarcinoma
7 66185 12 26300000 27700000 Gain TM7SF3 Barrett''s adenocarcinoma
8 73111 12 91200000 94800000 Gain KRT19P2 Barrett''s adenocarcinoma
9 74577 13 109100000 114142980 Gain Barrett''s adenocarcinoma
10 75797 13 24400000 26700000 Gain Barrett''s adenocarcinoma
11 79796 13 77800000 86500000 Gain SOX1 Barrett''s adenocarcinoma
12 81034 14 100400000 102200000 Gain SLC25A29 Barrett''s adenocarcinoma
13 88798 14 95400000 100400000 Gain TCL1A Barrett''s adenocarcinoma
14 88799 14 95400000 100400000 Gain TCL1B Barrett''s adenocarcinoma
15 107009 17 11200000 15900000 Loss RICH2 Barrett''s adenocarcinoma
16 114436 17 47600000 54900000 Gain CUEDC1 Barrett''s adenocarcinoma
17 115246 17 55600000 58400000 Gain LRRC37A3 Barrett''s adenocarcinoma
18 116543 17 6800000 11200000 Loss MYH13 Barrett''s adenocarcinoma
19 116544 17 6800000 11200000 Loss TP53 Barrett''s adenocarcinoma
20 122243 18 54400000 57100000 Loss Barrett''s adenocarcinoma
21 125938 19 16100000 19800000 Gain AP1M1 Barrett''s adenocarcinoma
22 127254 19 30200000 37100000 Gain ZNF536 Barrett''s adenocarcinoma
23 134771 2 106700000 108600000 Gain GCC2 Barrett''s adenocarcinoma
24 141056 2 205600000 209100000 Gain Barrett''s adenocarcinoma
25 144816 2 29800000 31900000 Gain ALK Barrett''s adenocarcinoma
26 151523 20 22300000 25700000 Gain SSTR4 Barrett''s adenocarcinoma
27 151524 20 22300000 25700000 Loss CST4 Barrett''s adenocarcinoma
28 152533 20 31500000 33900000 Gain CEP250 Barrett''s adenocarcinoma
29 154854 20 49200000 54400000 Gain CBLN4 Barrett''s adenocarcinoma
30 170891 3 161200000 169200000 Gain BCHE Barrett''s adenocarcinoma
31 172565 3 184200000 186000000 Gain MAGEF1 Barrett''s adenocarcinoma
32 172566 3 184200000 186000000 Gain MUC13 Barrett''s adenocarcinoma
33 172567 3 184200000 186000000 Gain VPS8 Barrett''s adenocarcinoma
34 177566 3 58500000 63700000 Loss Barrett''s adenocarcinoma
35 196847 5 172200000 176500000 Gain MSX2 Barrett''s adenocarcinoma
36 203652 6 1 2300000 Gain Barrett''s adenocarcinoma
37 204555 6 11200000 13500000 Gain PHACTR1 Barrett''s adenocarcinoma
38 205460 6 127300000 130400000 Gain C6orf190 Barrett''s adenocarcinoma
39 205461 6 127300000 130400000 Gain PTPRK Barrett''s adenocarcinoma
40 212308 6 36800000 40600000 Gain DNAH8 Barrett''s adenocarcinoma
41 219021 7 120900000 123600000 Loss SLC13A1 Barrett''s adenocarcinoma
42 219022 7 120900000 123600000 Loss TAS2R16 Barrett''s adenocarcinoma
43 225150 7 43300000 46600000 Gain RAMP3 Barrett''s adenocarcinoma
44 225833 7 50900000 53900000 Gain Barrett''s adenocarcinoma
45 227260 7 66100000 71800000 Gain CALN1 Barrett''s adenocarcinoma
46 227261 7 66100000 71800000 Gain WBSCR17 Barrett''s adenocarcinoma
47 227796 7 7200000 13300000 Gain ICA1 Barrett''s adenocarcinoma
48 231014 8 101600000 106100000 Gain ANKRD46 Barrett''s adenocarcinoma
49 231021 8 101600000 106100000 Gain RNF19 Barrett''s adenocarcinoma
50 232059 8 110600000 112200000 Gain PKHD1L1 Barrett''s adenocarcinoma

Expression for Barrett's Adenocarcinoma

Search GEO for disease gene expression data for Barrett's Adenocarcinoma.

Pathways for Barrett's Adenocarcinoma

Pathways related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.58 ERBB2 KRAS PTGS2 TP53
2
Show member pathways
12.4 OGG1 RAD51 TP53 XRCC1
3
Show member pathways
12.29 ERBB2 KRAS RAD51 TP53
4
Show member pathways
12.28 CDKN2A ERBB2 FHIT KRAS TP53
5 12.17 CDKN2A RAD51 TP53 XRCC1
6 12.13 CDKN2A ERBB2 KRAS PTGS2 TP53
7 11.97 KRAS PTGS2 TP53
8 11.93 KRAS RAD51 TP53
9
Show member pathways
11.89 ADIPOR1 KRAS TP53
10 11.82 CDKN2A KRAS TP53
11 11.7 CDKN2A KRAS TP53
12 11.7 CDKN2A ERBB2 KRAS PTGS2 RAD51 TP53
13 11.68 CDKN2A ERBB2 KRAS TP53
14 11.53 FHIT PTGS2 TP53
15 11.36 ERBB2 KRAS TP53
16 11.32 CDKN2A ERBB2 KRAS TP53
17 11.12 CDKN2A ERBB2 GSTT2 TP53
18 10.9 CDKN2A TP53
19
Show member pathways
10.89 CDKN2A TP53

GO Terms for Barrett's Adenocarcinoma

Cellular components related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.17 CDKN2A COX7A2 FHIT KRAS OGG1 RAD51

Biological processes related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 11)
id Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.78 OGG1 RAD51 TP53 XRCC1
2 response to drug GO:0042493 9.62 OGG1 PTGS2 RAD51 XRCC1
3 positive regulation of gene expression GO:0010628 9.61 ERBB2 KRAS TP53
4 negative regulation of cell growth GO:0030308 9.58 ADIPOR1 CDKN2A TP53
5 cellular response to gamma radiation GO:0071480 9.49 RAD51 TP53
6 response to X-ray GO:0010165 9.46 RAD51 TP53
7 replicative senescence GO:0090399 9.37 CDKN2A TP53
8 Ras protein signal transduction GO:0007265 9.33 CDKN2A KRAS TP53
9 positive regulation of cellular senescence GO:2000774 9.26 CDKN2A KRAS
10 negative regulation of immature T cell proliferation in thymus GO:0033088 8.96 CDKN2A ERBB2
11 base-excision repair GO:0006284 8.8 OGG1 TP53 XRCC1

Molecular functions related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.55 ADIPOR1 ERBB2 FHIT RAD51 TP53
2 nucleotide binding GO:0000166 9.26 ERBB2 FHIT KRAS RAD51
3 damaged DNA binding GO:0003684 8.8 OGG1 TP53 XRCC1

Sources for Barrett's Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....